Given the increasing need for collaboration in therapy development, Dr. Kubassova and Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies.
Dr. Kubassova will discuss the challenges biotechnology companies face in the industry and will explain IAG’s unique approach to solving these problems.
Following Successful Completion of LANTERN-1 Clinical Trial.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).
In addition to the corporate headquarters in London, UK and operational offices in EU, the new office space in Philadelphia will enable IAG’ team to continue expansion of our global network of scientific and medical collaborators, while being within easy reach of strategic partners.
